105 related articles for article (PubMed ID: 38714106)
1. Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma.
Scatolini M; Grisanti S; Tomaiuolo P; Grosso E; Basile V; Cosentini D; Puglisi S; Laganà M; Perotti P; Saba L; Rossini E; Palermo F; Sigala S; Volante M; Berruti A; Terzolo M
Eur J Cancer; 2024 Jul; 205():114088. PubMed ID: 38714106
[TBL] [Abstract][Full Text] [Related]
2. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA; Bilen MA
Oncologist; 2022 Jun; 27(6):462-468. PubMed ID: 35462410
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of TP53 alterations in adrenocortical carcinomas.
Waldmann J; Patsalis N; Fendrich V; Langer P; Saeger W; Chaloupka B; Ramaswamy A; Fassnacht M; Bartsch DK; Slater EP
Langenbecks Arch Surg; 2012 Feb; 397(2):209-16. PubMed ID: 22203015
[TBL] [Abstract][Full Text] [Related]
4. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.
Raymond VM; Else T; Everett JN; Long JM; Gruber SB; Hammer GD
J Clin Endocrinol Metab; 2013 Jan; 98(1):E119-25. PubMed ID: 23175693
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
8. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
9. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
10. Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma.
Akhavanfard S; Yehia L; Padmanabhan R; Reynolds JP; Ni Y; Eng C
Hum Mol Genet; 2021 Jan; 29(22):3679-3690. PubMed ID: 33326033
[TBL] [Abstract][Full Text] [Related]
11. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.
Dos Santos Passaia B; Lima K; Kremer JL; da Conceição BB; de Paula Mariani BM; da Silva JCL; Zerbini MCN; Fragoso MCBV; Machado-Neto JA; Lotfi CFP
Invest New Drugs; 2020 Jun; 38(3):899-908. PubMed ID: 31441020
[TBL] [Abstract][Full Text] [Related]
12. CCNB2 and AURKA overexpression may cause atypical mitosis in Japanese cortisol-producing adrenocortical carcinoma with TP53 somatic variant.
Ikeya A; Nakashima M; Yamashita M; Kakizawa K; Okawa Y; Saitsu H; Sasaki S; Sasano H; Suda T; Oki Y
PLoS One; 2020; 15(4):e0231665. PubMed ID: 32287321
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status.
Brenna CTA; Michaeli O; Wasserman JD; Malkin D
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e635-e641. PubMed ID: 33122580
[TBL] [Abstract][Full Text] [Related]
14. Sum of High-Risk Gene Mutation (SHGM): A Novel Attempt to Assist Differential Diagnosis for Adrenocortical Carcinoma with Benign Adenoma, Based on Detection of Mutations of Nine Target Genes.
Zheng GY; Zhang XB; Li HZ; Zhang YS; Deng JH; Wu XC
Biochem Genet; 2021 Aug; 59(4):902-918. PubMed ID: 33564960
[TBL] [Abstract][Full Text] [Related]
15. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
16. Coincidence of primary adrenocortical carcinoma and melanoma: three CASE reports.
Ko YL; Kumar V; Lippert J; Diaz-Cano S; Skordilis K; Kimpel O; Kircher S; Asia M; Elhassan YS; Altieri B; Ronchi CL
BMC Endocr Disord; 2023 Jan; 23(1):4. PubMed ID: 36604647
[TBL] [Abstract][Full Text] [Related]
17. Adrenocortical carcinoma (ACC): When and why should we consider germline testing?
Petr EJ; Else T
Presse Med; 2018; 47(7-8 Pt 2):e119-e125. PubMed ID: 30104051
[TBL] [Abstract][Full Text] [Related]
18. Familial Adrenocortical Carcinoma in Association With Lynch Syndrome.
Challis BG; Kandasamy N; Powlson AS; Koulouri O; Annamalai AK; Happerfield L; Marker AJ; Arends MJ; Nik-Zainal S; Gurnell M
J Clin Endocrinol Metab; 2016 Jun; 101(6):2269-72. PubMed ID: 27144940
[TBL] [Abstract][Full Text] [Related]
19. Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma.
Heinze B; Herrmann LJ; Fassnacht M; Ronchi CL; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
Eur J Endocrinol; 2014 May; 170(5):707-17. PubMed ID: 24566897
[TBL] [Abstract][Full Text] [Related]
20. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
Fojo T; Huff L; Litman T; Im K; Edgerly M; Del Rivero J; Pittaluga S; Merino M; Bates SE; Dean M
BMC Med Genomics; 2020 Nov; 13(1):165. PubMed ID: 33148256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
